HONG KONG – Celltrion Inc. had a seven-year partnership with Pfizer Inc.'s new subsidiary, Hospira Inc., to develop two biosimilar assets, but those ties were severed last week when Pfizer cut loose the rights for the two assets, saying that it plans to focus on a pipeline of in-house developed biosimilars.